Characteristics of treatment-naive CLL patients included in this study
| ID . | Sex . | Age, y . | Rai stage . | Mutation status . | Leukocyte count, ×109/L . | % CD5+CD19+ . | % CD3+ . | CMV status . | 
|---|---|---|---|---|---|---|---|---|
| 1 | Male | 58 | II | M | 43.0 | 93.0 | 6 | + | 
| 2 | Male | 58 | II | ? | 27.8 | 96.0 | 0 | − | 
| 3 | Male | 50 | 0 | UM | 77.7 | 73.1 | 14.74 | + | 
| 4 | Male | 75 | ? | M | ? | 89.6 | 5.75 | − | 
| 5 | Female | 63 | II | M | 113.0 | 88.3 | 4.35 | + | 
| 6 | Female | 62 | 0 | M | 24.7 | 88.0 | 4.17 | − | 
| 7 | Male | 60 | 0 | UM | 21.9 | 99.2 | 8.7 | ? | 
| 8 | Female | 62 | ? | UM | 74.6 | 99.7 | 2.7 | ? | 
| 9 | Female | 62 | 0 | M | 46.1 | 91.1 | 6.7 | + | 
| 10 | Female | 65 | 0 | UM | 51.4 | 64.9 | 5.3 | ? | 
| 11 | Male | 74 | II | ? | 68.9 | 88.4 | 1.8 | + | 
| 12 | Female | 64 | I | M | 33.0 | 86.6 | 10.1 | − | 
| 13 | Female | 67 | 0 | P | 45.7 | 85.4 | 9.6 | + | 
| 14 | Male | 66 | I | ? | 32.1 | 78.1 | 11.7 | + | 
| 15 | Female | 56 | 0 | UM | 90.3 | 96.4 | 3.1 | − | 
| 16 | Male | 79 | 0 | M | 65.1 | 92.5 | 2.1 | + | 
| 17 | Male | 41 | I | M | 40.0 | 91.4 | 6 | − | 
| 18 | Male | 79 | 0 | UM | 100.0 | 94.1 | 6.4 | − | 
| 19 | Male | 55 | 0 | M | 85.6 | 84.0 | 9.6 | ? | 
| 20 | Female | 69 | 0 | P | ? | ? | ? | + | 
| 21 | Male | 56 | 0 | M | 93.9 | 84.3 | 3.5 | + | 
| 22 | Male | 85 | 0 | ? | 36.5 | 86.1 | 10.5 | + | 
| 23 | Male | 61 | 0 | M | 74.5 | ? | ? | + | 
| 24 | Male | 80 | 0 | M | 86.4 | 93.4 | 2.8 | + | 
| 25 | Female | 57 | 0 | ? | 52.9 | 80.9 | 11.6 | + | 
| 26 | Female | 60 | 0 | UM | 52.6 | 87.3 | 9 | + | 
| 27 | Male | 61 | 0 | UM | 60.2 | 92.8 | 4 | + | 
| 28 | Female | 67 | 0 | P | 48.3 | 93.6 | 5.8 | − | 
| 29 | Male | 75 | ? | ? | 33.7 | 10.6* | 8.3 | + | 
| 30 | Female | 75 | 0 | UM | 50.0 | 78.3 | 3.6 | − | 
| 31 | Male | 67 | II | M | 122.1 | 85.3 | 1.7 | + | 
| 32 | Female | 64 | II | M | 30.8 | 76.7 | 10.7 | ? | 
| 33 | Male | 63 | 0 | M | 72.1 | 94.7 | 4 | + | 
| 34 | Male | 55 | I | UM | 51.7 | 65.2 | 8.5 | − | 
| 35 | Male | 74 | 0 | M | 105.7 | 92.7 | 2.8 | + | 
| 36 | Male | 50 | I | UM | 47.4 | 70.9 | 6.3 | − | 
| 37 | Male | 51 | I | UM | 51.3 | 85.1 | 3.5 | + | 
| 38 | Male | 58 | I | UM | 42.1 | 91.5 | 4.9 | + | 
| 39 | Female | 88 | 0 | M | 177.6 | 95.4 | 2.4 | − | 
| 40 | Female | 76 | 0 | ? | 31.1 | ? | ? | ? | 
| 41 | Female | 80 | 0 | ? | 142.2 | 95.1 | 1.4 | − | 
| 42 | Male | 57 | II | UM | 84.7 | 90.7 | 3.6 | + | 
| 43 | Male | 83 | ? | M | 60.6 | 96.9 | 2.4 | − | 
| 44 | Male | 74 | 0 | M | 61.3 | 87.7 | 5.2 | + | 
| 45 | Male | 81 | II | ? | 88.7 | 95.5 | 2.5 | + | 
| 46 | Female | 63 | 0 | M | 43.9 | 94.3 | 4.8 | + | 
| 47 | Male | 66 | II | M | 23.1 | 90.5 | 7.9 | + | 
| 48 | Male | 79 | 0 | ? | 39.0 | 92.0 | 3.4 | − | 
| 49 | Male | 65 | I | ? | 132.7 | 96.9 | 1.2 | ? | 
| 50 | Male | 79 | 0 | ? | 127.8 | 97.1 | 2.1 | + | 
| 51 | Male | 46 | I | UM | 180.0 | 93.9 | 1.2 | − | 
| 52 | Male | 64 | I | ? | 155.8 | 94.6 | 3.6 | + | 
| 53 | Female | 64 | I | M | 113.3 | 93.5 | 5.2 | ? | 
| 54 | Female | 72 | ? | ? | 745.0 | 79.5 | 4.4 | + | 
| 55 | Female | 79 | 0 | M | 83.8 | 93.5 | 4 | + | 
| 56 | Male | 72 | 0 | M | 202.0 | 95.0 | 2 | − | 
| 57 | Male | 68 | ? | UM | 268.4 | 97.2 | 1.5 | + | 
| 58 | Female | 80 | I | M | 65.3 | 93.7 | 4.9 | + | 
| 59 | Female | 56 | ? | M | 87.2 | 94.3 | 4 | ? | 
| 60 | Male | 68 | 0 | ? | 119.0 | 98.0 | 1.55 | − | 
| 61 | Male | 69 | 0 | ? | 145.7 | 95 | 3.2 | ? | 
| 62 | Female | 81 | 0 | UM | 63 | 85.9 | 14.3 | ? | 
| ID . | Sex . | Age, y . | Rai stage . | Mutation status . | Leukocyte count, ×109/L . | % CD5+CD19+ . | % CD3+ . | CMV status . | 
|---|---|---|---|---|---|---|---|---|
| 1 | Male | 58 | II | M | 43.0 | 93.0 | 6 | + | 
| 2 | Male | 58 | II | ? | 27.8 | 96.0 | 0 | − | 
| 3 | Male | 50 | 0 | UM | 77.7 | 73.1 | 14.74 | + | 
| 4 | Male | 75 | ? | M | ? | 89.6 | 5.75 | − | 
| 5 | Female | 63 | II | M | 113.0 | 88.3 | 4.35 | + | 
| 6 | Female | 62 | 0 | M | 24.7 | 88.0 | 4.17 | − | 
| 7 | Male | 60 | 0 | UM | 21.9 | 99.2 | 8.7 | ? | 
| 8 | Female | 62 | ? | UM | 74.6 | 99.7 | 2.7 | ? | 
| 9 | Female | 62 | 0 | M | 46.1 | 91.1 | 6.7 | + | 
| 10 | Female | 65 | 0 | UM | 51.4 | 64.9 | 5.3 | ? | 
| 11 | Male | 74 | II | ? | 68.9 | 88.4 | 1.8 | + | 
| 12 | Female | 64 | I | M | 33.0 | 86.6 | 10.1 | − | 
| 13 | Female | 67 | 0 | P | 45.7 | 85.4 | 9.6 | + | 
| 14 | Male | 66 | I | ? | 32.1 | 78.1 | 11.7 | + | 
| 15 | Female | 56 | 0 | UM | 90.3 | 96.4 | 3.1 | − | 
| 16 | Male | 79 | 0 | M | 65.1 | 92.5 | 2.1 | + | 
| 17 | Male | 41 | I | M | 40.0 | 91.4 | 6 | − | 
| 18 | Male | 79 | 0 | UM | 100.0 | 94.1 | 6.4 | − | 
| 19 | Male | 55 | 0 | M | 85.6 | 84.0 | 9.6 | ? | 
| 20 | Female | 69 | 0 | P | ? | ? | ? | + | 
| 21 | Male | 56 | 0 | M | 93.9 | 84.3 | 3.5 | + | 
| 22 | Male | 85 | 0 | ? | 36.5 | 86.1 | 10.5 | + | 
| 23 | Male | 61 | 0 | M | 74.5 | ? | ? | + | 
| 24 | Male | 80 | 0 | M | 86.4 | 93.4 | 2.8 | + | 
| 25 | Female | 57 | 0 | ? | 52.9 | 80.9 | 11.6 | + | 
| 26 | Female | 60 | 0 | UM | 52.6 | 87.3 | 9 | + | 
| 27 | Male | 61 | 0 | UM | 60.2 | 92.8 | 4 | + | 
| 28 | Female | 67 | 0 | P | 48.3 | 93.6 | 5.8 | − | 
| 29 | Male | 75 | ? | ? | 33.7 | 10.6* | 8.3 | + | 
| 30 | Female | 75 | 0 | UM | 50.0 | 78.3 | 3.6 | − | 
| 31 | Male | 67 | II | M | 122.1 | 85.3 | 1.7 | + | 
| 32 | Female | 64 | II | M | 30.8 | 76.7 | 10.7 | ? | 
| 33 | Male | 63 | 0 | M | 72.1 | 94.7 | 4 | + | 
| 34 | Male | 55 | I | UM | 51.7 | 65.2 | 8.5 | − | 
| 35 | Male | 74 | 0 | M | 105.7 | 92.7 | 2.8 | + | 
| 36 | Male | 50 | I | UM | 47.4 | 70.9 | 6.3 | − | 
| 37 | Male | 51 | I | UM | 51.3 | 85.1 | 3.5 | + | 
| 38 | Male | 58 | I | UM | 42.1 | 91.5 | 4.9 | + | 
| 39 | Female | 88 | 0 | M | 177.6 | 95.4 | 2.4 | − | 
| 40 | Female | 76 | 0 | ? | 31.1 | ? | ? | ? | 
| 41 | Female | 80 | 0 | ? | 142.2 | 95.1 | 1.4 | − | 
| 42 | Male | 57 | II | UM | 84.7 | 90.7 | 3.6 | + | 
| 43 | Male | 83 | ? | M | 60.6 | 96.9 | 2.4 | − | 
| 44 | Male | 74 | 0 | M | 61.3 | 87.7 | 5.2 | + | 
| 45 | Male | 81 | II | ? | 88.7 | 95.5 | 2.5 | + | 
| 46 | Female | 63 | 0 | M | 43.9 | 94.3 | 4.8 | + | 
| 47 | Male | 66 | II | M | 23.1 | 90.5 | 7.9 | + | 
| 48 | Male | 79 | 0 | ? | 39.0 | 92.0 | 3.4 | − | 
| 49 | Male | 65 | I | ? | 132.7 | 96.9 | 1.2 | ? | 
| 50 | Male | 79 | 0 | ? | 127.8 | 97.1 | 2.1 | + | 
| 51 | Male | 46 | I | UM | 180.0 | 93.9 | 1.2 | − | 
| 52 | Male | 64 | I | ? | 155.8 | 94.6 | 3.6 | + | 
| 53 | Female | 64 | I | M | 113.3 | 93.5 | 5.2 | ? | 
| 54 | Female | 72 | ? | ? | 745.0 | 79.5 | 4.4 | + | 
| 55 | Female | 79 | 0 | M | 83.8 | 93.5 | 4 | + | 
| 56 | Male | 72 | 0 | M | 202.0 | 95.0 | 2 | − | 
| 57 | Male | 68 | ? | UM | 268.4 | 97.2 | 1.5 | + | 
| 58 | Female | 80 | I | M | 65.3 | 93.7 | 4.9 | + | 
| 59 | Female | 56 | ? | M | 87.2 | 94.3 | 4 | ? | 
| 60 | Male | 68 | 0 | ? | 119.0 | 98.0 | 1.55 | − | 
| 61 | Male | 69 | 0 | ? | 145.7 | 95 | 3.2 | ? | 
| 62 | Female | 81 | 0 | UM | 63 | 85.9 | 14.3 | ? | 
+, positive; −, negative; ?, unknown; CMV, cytomegalovirus; M, mutated; P, polyclonal; UM, unmutated.
CLL cells in this patient had low CD5 expression. CD19+ fraction in this patient is 84.7%